Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial

This publication has 30 references indexed in Scilit:

• LATE NORMAL TISSUE SEQUELAE IN THE SECOND DECADE AFTER HIGH DOSE RADIATION THERAPY WITH COMBINED PHOTONS AND CONFORMAL PROTONS FOR LOCALLY ADVANCED PROSTATE CANCER
  Journal of Urology, 2002
• A phase III trial comparing whole-pelvic (WP) to prostate only (PO) radiotherapy and neoadjuvant to adjuvant total androgen suppression (TAS): preliminary analysis of RTOG 9413
  International Journal of Radiation Oncology*Biology*Physics, 2001
• HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED PROSTATE CANCER
  Journal of Urology, 2001
• Radiation dose response in patients with favorable localized prostate cancer (Stage T1–T2, biopsy Gleason ≤ 6, and pretreatment prostate-specific antigen ≤ 10)
  International Journal of Radiation Oncology*Biology*Physics, 2001
• Influence of Prostate-Specific Antigen Testing on the Spectrum of Patients With Prostate Cancer Undergoing Radical Prostatectomy at a Large Referral Practice
  Mayo Clinic Proceedings, 1998
• External beam radiotherapy for stage T1/T2 prostate cancer: how does it stack up?
  Urology, 1998
• Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: Further evidence for a significant dose effect
  International Journal of Radiation Oncology*Biology*Physics, 1996
• Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)
  International Journal of Radiation Oncology*Biology*Physics, 1995
• Late effects toxicity scoring: The soma scale
  International Journal of Radiation Oncology*Biology*Physics, 1995
• Sample size requirements and length of study for testing interaction in a 1 × k factorial design when time-to-failure is the outcome
  Controlled Clinical Trials, 1993